COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Merck KGaA: Merck confirms late-stage discussions with SpringWorks Therapeutics, Inc. on potential acquisition
Merck KGaA confirms late-stage discussions with SpringWorks Therapeutics, Inc. on potential acquisition, at around USD 47 per share. No final decision or binding agreement yet -
-
-
COMMUNIQUÉ DE PRESSE
GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Société
-
COMMUNIQUÉ DE PRESSE
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
GENFIT reports full-year 2024 financial results and corporate update. Net profit of €1.5 million, Iqirvo® commercial launch in PBC, new ACLF datasets, royalty financing. CEO, Pascal Prigent shares progress and outlook -
COMMUNIQUÉ DE PRESSE
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
Inventiva announces publication in Clinical Gastroenterology and Hepatology of non-invasive biomarker signatures predictive of histological response in MASH patients treated with lanifibranor -
COMMUNIQUÉ DE PRESSE
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor
Inventiva annonce la publication des résultats de l'analyse de nouvelles signatures de biomarqueurs non invasifs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor -
-
